Research programme: anticancer fusion toxins - Viscum AG

Drug Profile

Research programme: anticancer fusion toxins - Viscum AG

Alternative Names: Anticancer fusion toxins research programme - Viscum AG

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator VISCUM AG
  • Class
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Apr 2007 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 20 Nov 2003 A preclinical study has been added to the Cancer pharmacodynamics section
  • 08 Oct 2003 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top